Etizolam

Any pre-existing respiratory compromise increases the risk of clinically significant respiratory depression with etizolam. Class-level contraindication for all benzodiazepine-site agonists.

Benzodiazepine-class contraindication. GABA-A positive allosteric modulation reduces upper airway muscle tone and central respiratory drive, worsening both obstructive and central sleep apnea. No etizolam-specific sleep apnea data; inferred from benzodiazepine class evidence.

Benzodiazepine-class contraindication. GABA-A positive allosteric modulation reduces motor neuron excitability, worsening the already-compromised neuromuscular transmission in myasthenia gravis. No etizolam-specific data; inferred from diazepam and other benzodiazepine class evidence.

Etizolam's high binding affinity and rapid onset predict strong interoceptive reinforcement cues. Tamburin et al. (2020) documented prescription-to-dependence trajectories in 11 patients originally prescribed etizolam for medical indications, all of whom escalated to supratherapeutic doses.

CYP2C19 poor metabolizers (3–5% European, 15–20% East Asian populations) already experience 2.65-fold higher AUC. Adding a CYP3A4 inhibitor (itraconazole, ketoconazole, clarithromycin, HIV protease inhibitors) increases AUC to 6.18-fold above normal. If co-administration is clinically necessary, substantial dose reduction is required. This is an etizolam-specific pharmacogenomic interaction quantified by Yamamoto et al. (2017).

Benzodiazepine class contraindication. Associated with neonatal withdrawal, floppy infant syndrome, and possible teratogenic effects. No etizolam-specific teratogenicity or reproductive toxicity data have been published.

Elderly patients show increased sensitivity to CNS depressant effects, higher fall risk, and potentially slower CYP-mediated metabolism. NCT00707915 specifically investigated cognitive and motor effects of benzodiazepine-derivative discontinuation in elderly patients.

The combination of etizolam with opioids — particularly fentanyl and its analogues — produces synergistic CNS and respiratory depression and is the primary driver of etizolam-associated mortality. In Ontario (2017–2021), etizolam was the most frequently detected benzodiazepine in 11,033 opioid-positive death investigations. This combination is never safe at any dose.

Alcohol and etizolam both enhance GABAergic inhibitory neurotransmission, producing additive CNS and respiratory depression. Class-level contraindication; no etizolam-specific controlled data, but the mechanism is pharmacologically unambiguous.

Benzodiazepine-class contraindication. Mydriatic effects associated with benzodiazepine-site agonists may worsen or precipitate acute angle-closure glaucoma. No etizolam-specific ophthalmological data; inferred from benzodiazepine class evidence.